# Aromatase Inhibitor and Durvalumab in Postmenopausal Breast Cancer

> **NCT03874325** · PHASE2 · TERMINATED · sponsor: **H. Lee Moffitt Cancer Center and Research Institute** · enrollment: 17 (actual)

## Conditions studied

- Breast Cancer
- Hormone Receptor Positive Tumor

## Interventions

- **DRUG:** Durvalumab
- **DRUG:** Anastrozole 1mg
- **DRUG:** Letrozole 2.5mg
- **DRUG:** Exemestane 25 MG

## Key facts

- **NCT ID:** NCT03874325
- **Lead sponsor:** H. Lee Moffitt Cancer Center and Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-04-26
- **Primary completion:** 2020-11-15
- **Final completion:** 2021-01-06
- **Target enrollment:** 17 (ACTUAL)
- **Why stopped:** lost funding
- **Last updated:** 2022-05-31

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03874325

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03874325, "Aromatase Inhibitor and Durvalumab in Postmenopausal Breast Cancer". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT03874325. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*